{"filings":[{"id":2383316,"accession_number":"0001104659-26-099247","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-08-20T20:33:15+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Abbott settles NEC litigation for $670M covering Gill case and ~2,000 infants","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Agreements resolve $495M Gill verdict plus NEC claims for ~2,000 infants, total ~$670M.","Avoids paying ~$600M (Gill judgment plus interest); settlement includes no admission of liability.","Following settlement, ~1,700 lawsuits pending involving ~12,700 infants; company to work to eliminate invalid claims.","Abbott and medical groups assert no reliable scientific evidence that preterm formulas cause NEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-20","daily_digest_url":"/daily/2026-08-20","daily_digest_rank":7},{"id":1673877,"accession_number":"0001628280-26-048377","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-07-16T11:36:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q2 adjusted EPS $1.31; raises FY2026 EPS guidance to $5.45-$5.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 reported sales $12.6B (+13.0% reported, +4.8% comparable); GAAP EPS $0.53, adjusted EPS $1.31.","Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58; comparable sales growth reaffirmed at 6.5%-7.5%.","Medical Devices comparable sales +8.4%; Diabetes Care CGM comparable sales +9.5%.","Returned $2.1B to shareholders in Q2 via dividends and share repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95547,"accession_number":"0001104659-26-049434","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Abbott adds Kevin Conroy to board; shareholders approve 2026 Incentive Stock Program","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Conroy appointed to Abbott's Board of Directors effective April 24, 2026.","Shareholders approved the 2026 Incentive Stock Program authorizing up to 140 million shares, replacing the 2017 plan.","Board size increased from 12 to 13 directors via bylaw amendment effective April 24, 2026.","The 2026 Program has a ten-year term and permits stock options, RSUs, performance awards, and other equity grants.","All director nominees were elected; Ernst & Young ratified as independent auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95546,"accession_number":"0001104659-26-044892","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abbott reaches settlement in shareholder derivative suit over infant formula; governance reforms, up to $15.85M fees","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement of consolidated derivative action alleging fiduciary breaches and securities violations related to infant formula recall.","Abbott to adopt corporate governance reforms; no admission of wrongdoing.","Lead plaintiffs' counsel seeks up to $15.85M in fees/expenses and service awards up to $15,000 each.","Court approval hearing set for June 4, 2026; shareholder objections due by May 18, 2026.","Dismissal with prejudice of all claims; governance enhancements to improve compliance oversight."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95545,"accession_number":"0001628280-26-025365","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q1 adj. EPS $1.15, +6% YoY; acquires Exact Sciences; FY guidance $5.38-$5.58","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP diluted EPS $0.61; adjusted diluted EPS $1.15 (+6% YoY).","Q1 sales $11.16B, reported +7.8%, comparable +3.7%.","Completed Exact Sciences acquisition March 23; adds $0.20 dilution to FY EPS guidance.","FY2026 guidance: comparable sales growth 6.5%-7.5%; adjusted EPS $5.38-$5.58.","Medical Devices +8.5% comparable; Diabetes CGM +7.6% comparable; Nutrition -7.7% comparable."],"consensus_eps_estimate":null,"consensus_eps_actual":0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":11164000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108695,"accession_number":"0001104659-26-033079","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.","Exact Sciences last trading day was March 20, 2026; shares converted to $105 cash.","Deal adds Cologuard, Oncotype DX, Oncodetect, Cancerguard cancer screening diagnostics.","Abbott becomes leader in $60B U.S. cancer screening and precision oncology diagnostics market.","Acquisition adds growth vertical to Abbott's high-single-digit growth expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108694,"accession_number":"0001104659-26-025240","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Abbott completes $20B senior notes offering to fund Exact Sciences acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $20B in eight tranches: Floating Rate Notes due 2029, fixed-rate notes from 3.700% to 5.600% with maturities 2029–2066.","Net proceeds to fund Exact Sciences acquisition (announced Nov 2025), repay Exact Sciences debt, pay fees, and general purposes.","If Exact Sciences acquisition not consummated by Feb 17, 2027, Abbott must redeem notes at 101% plus accrued interest.","Underwriters include Morgan Stanley, Barclays, BofA Securities, J.P. Morgan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108693,"accession_number":"0001104659-26-020509","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Abbott issues $20B multi-tranche notes; proceeds to fund Exact Sciences acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $20B in senior notes across 8 tranches: floating and fixed rates from 3.70% to 5.60%, maturities 2029-2066.","Net proceeds will fund the Exact Sciences acquisition, repay Exact Sciences debt, and for general corporate purposes.","Underwriters include Morgan Stanley, Barclays, BofA Securities, and J.P. Morgan Securities.","Closing expected on March 9, 2026, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108692,"accession_number":"0001104659-26-018167","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Abbott reduces board size from 13 to 12 directors effective April 24, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board of Directors amended Article III, Section 2 of By-Laws on February 20, 2026.","Board size reduced from 13 to 12 persons, effective April 24, 2026.","Amended By-Laws filed as Exhibit 3.1 to the Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108691,"accession_number":"0001628280-26-002982","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).","FY2025 adjusted EPS $5.15 (+10% YoY); revenue $44.3B (+5.7% reported, +6.7% ex-COVID).","FY2026 guidance: organic sales growth 6.5%-7.5%; adjusted EPS $5.55-$5.80 (midpoint +10%).","Medical Devices sales +12.3% reported (+10.4% organic); CGM sales $2.0B up 15% reported.","Agreed to acquire Exact Sciences (cancer diagnostics); close expected Q2 2026. FDA OK for Volt PFA System."],"consensus_eps_estimate":null,"consensus_eps_actual":3.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":44328000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125137,"accession_number":"0001104659-25-120657","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Abbott names Nita Ahuja to Board of Directors; board expands to 13 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nita Ahuja, M.D. appointed to Abbott’s Board of Directors effective December 12, 2025.","Board size increased from 12 to 13 members via bylaw amendment on the same date.","Amended and restated by-laws filed as Exhibit 99.1; no additional details on Dr. Ahuja provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125136,"accession_number":"0001104659-25-114995","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.04","9.01"],"status":"ready","headline":"Abbott blackout period for retirement plan Dec 24 to Jan 11 due to admin changes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Blackout begins Dec 24, 2025 at 12pm CST, ends week of Jan 11, 2026.","Plans changing recordkeepers, trustees (U.S. Plan), and custodian (P.R. Plan).","Participants cannot change contributions, direct investments, take loans, or request distributions.","Directors and executive officers prohibited from trading Abbott equity during blackout per Regulation BTR.","No financial impact or change to company operations; routine administrative transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125135,"accession_number":"0001104659-25-114422","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Abbott to acquire Exact Sciences for $105/share, total equity value ~$21B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Abbot buys Exact Sciences for $105 per share in cash; equity value ~$21B, enterprise value ~$23B.","Exact Sciences 2025 revenue >$3B with high-teens organic growth; adds cancer diagnostics vertical.","Close expected Q2 2026, subject to Exact Sciences shareholder vote and regulatory approvals (incl. HSR).","Immediately accretive to Abbott's revenue growth (+50bps Abbott, +300bps Diagnostics) and gross margin (+100bps).","Financing via cash and up to $20B bridge loan from Morgan Stanley; initial 2026 debt/EBITDA ~2.7x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125134,"accession_number":"0001628280-25-045049","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).","Medical Devices up 14.8% reported, led by Diabetes Care CGM sales of $2.0B (+20.5% reported, +17.2% organic).","FY2025 organic sales guidance reaffirmed at 7.5-8.0% ex-COVID; adjusted EPS narrowed to $5.12-$5.18 (midpoint double-digit growth).","Adjusted operating margin improved 40bps to 23.0% of sales."],"consensus_eps_estimate":null,"consensus_eps_actual":2.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":32869000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141846,"accession_number":"0001628280-25-035135","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.","Total reported sales $11.14B, +7.4% reported, +6.9% organic, +7.5% ex-COVID tests.","Medical Devices organic growth 12.2%; Diabetes Care CGM sales $1.9B, +19.6% organic.","Full-year 2025 guidance: organic sales growth ex-COVID 7.5%-8.0%; adjusted EPS $5.10-$5.20.","Q3 2025 adjusted diluted EPS guidance $1.28-$1.32; adjusted operating margin ~23.5% for FY."],"consensus_eps_estimate":null,"consensus_eps_actual":1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":21500000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159784,"accession_number":"0001104659-25-043508","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abbott General Counsel Hubert L. Allen to retire after transition period","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hubert L. Allen, EVP, General Counsel and Secretary, notified Abbott on April 25, 2025 of his planned retirement.","Allen will remain with the company through a transition period; no replacement has been named.","Departure is described as retirement, not termination; no severance or change-in-control triggered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159783,"accession_number":"0001104659-25-040201","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abbott annual meeting results: all directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; Nancy McKinstry received 1.12B for vs 243.9M against (82%).","Ratification of Ernst & Young as independent auditor passed with 1.50B votes for, 36.6M against.","Advisory say-on-pay vote approved with 89.90% of votes cast in favor (1.22B for, 130.7M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159782,"accession_number":"0001628280-25-017924","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).","Reported revenue $10.36B (+4.0%), organic sales +6.9% (+8.3% ex-COVID testing).","Medical Devices sales +9.9% reported (+12.6% organic); FreeStyle Libre revenue $1.7B.","Full-year 2025 adjusted EPS guidance reaffirmed: $5.05-$5.25; Q2 adj. EPS $1.23-$1.27.","Volt PFA System received CE Mark; TECTONIC IVL pivotal trial initiated in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":10358000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178160,"accession_number":"0001628280-25-002092","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.","Q4 GAAP diluted EPS $5.27; adjusted diluted EPS $1.34 (core measure).","Full-year 2024 sales $42.0B (+4.6% reported); organic base business +9.6%; adjusted EPS $4.67.","Medical Devices Q4 sales $5.05B (+13.7% reported); Diabetes Care FreeStyle Libre grew 22.7% to $1.86B.","FY2025 guidance: organic sales growth 7.5%-8.5%; adjusted EPS $5.05-$5.25; op. margin 23.5%-24.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":7.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":41950000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194821,"accession_number":"0001104659-24-119717","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abbott extends change-in-control agreements for NEOs through Dec 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreements previously set to expire Dec 31, 2024, now extended to Dec 31, 2026.","Notification given to named executive officers on November 12, 2024.","Extension automatically continues term through second anniversary of original expiration date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194820,"accession_number":"0001628280-24-042893","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.","GAAP diluted EPS $0.94; adjusted diluted EPS $1.21; FY 2024 adj. EPS guidance raised to $4.64-$4.70.","FreeStyle Libre CGM sales >$1.6B (+20.7% organic); new $7B share repurchase authorized; quarterly dividend $0.55.","Partnered with Medtronic to connect CGM with insulin devices; launched OTC Lingo CGM in U.S.; completed VOLT-AF trial enrollment.","Nutrition organic +3.4% (Adult +9.1%); Diagnostics organic ex-COVID +3.3% (Core Lab +4.5%); Established Pharma organic +7.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":30976000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211113,"accession_number":"0001628280-24-032182","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).","FY2024 guidance raised: GAAP EPS $3.30-$3.40, adjusted $4.61-$4.71; organic sales growth 9.5%-10.0%.","Medical Devices organic growth 12.1%; FreeStyle Libre sales $1.6B (+20.4% organic).","New product approvals: Esprit BTK (FDA), Lingo/Libre Rio (FDA), AVEIR dual-chamber (CE Mark).","Quarterly dividend $0.55 payable Aug 15; 52nd consecutive year of dividend increase."],"consensus_eps_estimate":null,"consensus_eps_actual":1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":20341000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229641,"accession_number":"0001104659-24-055724","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abbott EVP Finance Robert Funck Jr. to retire July 1, 2024 after 36 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert E. Funck Jr., Executive Vice President, Finance, plans to retire effective July 1, 2024.","Funck has served at Abbott Laboratories for 36 years.","No successor has been named; Philip Boudreau remains Senior VP, Finance and CFO.","Departure is a planned retirement, not a termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229640,"accession_number":"0001104659-24-054016","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":[],"status":"ready","headline":"Abbott annual meeting results elect board, ratify auditor, approve executive compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 board nominees elected; Nancy McKinstry received ~242.6M against votes, John G. Stratton ~347.3M against.","Ernst & Young LLP ratified as auditor with 1.492B votes for, 42.9M against.","Advisory say-on-pay approved with 89.10% support (1.212B for, 144.2M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229639,"accession_number":"0001628280-24-016497","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q1 adj. EPS $0.98; raises FY2024 midpoint guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP diluted EPS $0.70; adjusted diluted EPS $0.98; revenue $9.96B (+2.2% reported).","Organic base business sales grew 10.8% YoY; fifth consecutive double-digit quarter.","FY2024 adjusted EPS guidance raised to $4.55-$4.70 midpoint; organic sales growth 8.5%-10.0% ex-COVID tests.","Medical Devices organic sales +14.3%; FreeStyle Libre revenue $1.5B (+22.4% reported).","FDA approved TriClip for tricuspid regurgitation and i-STAT TBI test; quarterly dividend $0.55/share maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":9964000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248160,"accession_number":"0001104659-24-007725","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Abbott enters new $5B unsecured revolving credit facility, terminates prior facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New 5-year revolving credit agreement with JPMorgan Chase as agent, effective Jan 29, 2024.","Facility allows up to $5B unsecured borrowings; no outstanding borrowings at closing.","Existing $5B facility dated Nov 2020 was terminated concurrently with no outstanding borrowings.","Interest based on base rate or SOFR plus margin tied to Abbott's credit ratings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248159,"accession_number":"0001628280-24-002009","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q4 adj EPS $1.19, base organic +11%; FY24 guide $4.50-$4.70","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $10.241B (+1.5%); organic base business growth +11.0% excluding COVID tests.","GAAP diluted EPS $0.91; adjusted diluted EPS $1.19. Full-year 2023 adjusted EPS $4.44.","FY2024 guidance: GAAP EPS $3.20-$3.40, adjusted EPS $4.50-$4.70; organic sales growth 8-10% ex-COVID.","Medical Devices sales +17.5% reported; FreeStyle Libre revenue $1.4B (+23.8% organic).","Nutrition sales +12.2% reported, +13.9% organic; U.S. infant formula regained market-leading position."],"consensus_eps_estimate":null,"consensus_eps_actual":3.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":40109000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265627,"accession_number":"0001628280-23-034544","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q3 adj EPS $1.14, rev $10.1B; raises FY23 EPS midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP EPS $0.82; adjusted EPS $1.14; reported sales $10.1B (-2.6% YoY).","Organic base-business sales (ex-COVID tests) up 13.8%; double-digit growth in all four segments.","Full-year 2023 adjusted EPS guidance raised to $4.42–$4.46 (midpoint $4.44 vs prior $4.30–$4.50).","Medical Devices organic growth 14.7%; FreeStyle Libre sales $1.4B (+28.5% organic).","Quarterly dividend maintained at $0.51/share; 399th consecutive quarterly payout."],"consensus_eps_estimate":null,"consensus_eps_actual":2.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":29868000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282828,"accession_number":"0001104659-23-097759","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K/A","filed_at":"2023-09-01T23:59:59+00:00","items":[],"status":"ready","headline":"Abbott amends 8-K to correct vote count against director Michael F. Roman","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corrected votes against Michael F. Roman: 25,575,883 (originally reported incorrectly).","Votes for Roman: 1,315,610,421; abstain: 2,597,363; broker non-votes: 179,678,846.","Amendment filed September 1, 2023; original 8-K filed May 2, 2023 for April 28 meeting.","No other changes to previously announced shareholder vote results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282829,"accession_number":"0001628280-23-025156","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q2 2023: Sales $10B, adjusted EPS $1.08; underlying base organic growth 11.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP diluted EPS $0.78; adjusted diluted EPS $1.08; revenue $9,978M, down 11.4% reported (COVID testing decline).","Underlying base business organic sales growth 11.5% led by Medical Devices (+14.2% organic) and Nutrition (+9.9% organic).","Full-year 2023 adjusted EPS guidance reaffirmed at $4.30-$4.50; COVID testing sales forecast $1.3B.","FreeStyle Libre sales $1.3B, up 24.7% organic; new product approvals: TactiFlex, AVEIR dual-chamber pacemaker.","Quarterly dividend $0.51/share declared, payable Aug 15, 2023; 51 consecutive years of increases."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":19725000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302159,"accession_number":"0001104659-23-070203","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":[],"status":"ready","headline":"Abbott appoints new EVP Finance, CFO, and Controller effective September 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert E. Funck, Jr. appointed Executive Vice President, Finance effective Sep 1, 2023.","Philip P. Boudreau promoted to Senior Vice President, Finance and CFO; base salary $600k, target bonus 90%.","John A. McCoy, Jr. appointed Vice President, Controller; was VP, Treasurer since 2021.","Boudreau and McCoy are internal promotions; all changes part of planned succession."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302156,"accession_number":"0001104659-23-069894","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K/A","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abbott Labs to hold annual say-on-pay vote after shareholder approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board determined to hold annual advisory vote on executive compensation, based on shareholder vote at April 28 annual meeting.","Previous 8-K (May 2, 2023) reported vote results; this amendment confirms the frequency decision.","No other material updates; routine governance action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302158,"accession_number":"0001104659-23-054706","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abbott shareholders elect all 12 director nominees, approve say-on-pay, reject four shareholder proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Nancy McKinstry received 329M against votes (24.6%); John Stratton received 373M against (27.9%).","Say-on-pay approved with 90.01% support; frequency vote set to annual with 97.86%.","Auditor Ernst & Young ratified with 98.9% support (1.505B votes for).","Four shareholder proposals all rejected; highest support was 30.46% for independent chair proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302157,"accession_number":"0001628280-23-012020","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q1 revenue $9.7B, adj EPS $1.03; base business organic growth 10.0%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $0.75; adjusted EPS $1.03; revenue $9.747B, down 18.1% reported, but organic base business up 10.0%.","Full-year 2023 adjusted EPS guidance unchanged at $4.30-$4.50; COVID testing-related sales forecast ~$1.5B.","Medical Devices organic sales grew 12.4%; FreeStyle Libre sales $1.2B with ~50% U.S. growth.","Nutrition organic sales up 10.3% (Pediatric +18.4% organic); Diagnostics ex-COVID tests organic +4.4%.","Dividend of $0.51/share declared, payable May 15; 51 consecutive years of dividend increases."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":9747000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321831,"accession_number":"0001104659-23-023291","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2023-02-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Abbott reduces board size from 13 to 12, effective April 28, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment to Article III, Section 2 of by-laws on Feb 17, 2023.","Board size reduced from 13 to 12 directors, effective April 28, 2023.","Amended by-laws filed as Exhibit 3.1 to the Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321830,"accession_number":"0001628280-23-001516","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q4 sales $10.1B, full-year GAAP EPS $3.91; guides FY23 adj. EPS $4.30-4.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $0.59; adjusted diluted EPS $1.03; full-year GAAP EPS $3.91, adjusted $5.34.","Full-year sales flat at $43.7B; organic growth 6.4%; COVID-testing sales $8.4B vs. $7.7B in 2021.","2023 guidance: GAAP EPS $3.05-3.25, adjusted EPS $4.30-4.50; organic growth ex-COVID high-single digits.","Quarterly dividend of $0.51 per share declared, payable Feb. 15, 2023; 51 consecutive years of increases.","FreeStyle Libre Q4 sales ~$1.1B; U.S. growth >40%; FDA approvals for Navitor TAVI and Eterna SCS."],"consensus_eps_estimate":null,"consensus_eps_actual":3.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":43653000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339939,"accession_number":"0001104659-22-125832","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Abbott amends by-laws to update shareholder nomination procedures and special meeting rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended and restated by-laws effective December 9, 2022.","Updates procedural mechanics for shareholder director nominations and proposals under Rule 14a-19.","Clarifies powers of Board and meeting chair to regulate conduct at shareholder meetings.","Includes ministerial changes and gender-neutral language updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339938,"accession_number":"0001104659-22-110612","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abbott extends change-in-control agreements with named executive officers through Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extension moves expiration date from Dec 31, 2022 to Dec 31, 2024 for named executive officers.","Agreements provide severance and other benefits upon a change in control of the company.","Previously reported Agreements with executive officers extended by two years effective Oct 18, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339937,"accession_number":"0001628280-22-026588","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-10-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott posts Q3 adj. EPS $1.15, revenue $10.4B; raises full-year EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP EPS $0.81, adjusted EPS $1.15; reported sales -4.7%, organic +1.3%.","Raises FY2022 adjusted EPS guidance to $5.17-$5.23; GAAP guidance $3.75-$3.81.","U.S. Medical Devices sales +11.3%; FreeStyle Libre revenues ~$1.0B in Q3.","COVID testing-related sales $1.7B in Q3 vs $1.9B a year ago; full-year outlook $7.8B.","Restarted infant formula production at Sturgis plant; quarterly dividend $0.47/share payable Nov. 15."],"consensus_eps_estimate":null,"consensus_eps_actual":3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":33562000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357245,"accession_number":"0001104659-22-100434","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Abbott appoints Claire Babineaux-Fontenot to Board; board size expanded to 13","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Claire Babineaux-Fontenot named to Abbott's Board of Directors effective September 15, 2022.","Board size increased from 12 to 13 directors via bylaw amendment on same date.","By-laws amended and restated to reflect new board size; Exhibit 3.1 filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357244,"accession_number":"0001104659-22-081006","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-07-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q2 EPS $1.14 GAAP, $1.43 adj; raises FY adj EPS view to $4.90+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $11.3B (+10.1% reported, +14.3% organic); GAAP EPS $1.14, adjusted EPS $1.43 (+22.2%).","COVID-19 testing sales $2.3B in Q2; full-year COVID testing revenue projected at $6.1B.","Raised FY 2022 GAAP EPS guidance to at least $3.50, adjusted EPS to at least $4.90.","Nutrition sales down 7.4% reported due to infant formula recall; Adult Nutrition organic growth +5.2%.","Medical Devices organic growth +7.5% driven by Diabetes Care FreeStyle Libre (+25.6% organic)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":23152000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375833,"accession_number":"0001104659-22-054704","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":[],"status":"ready","headline":"Abbott shareholders elect all 12 directors, reject 5 shareholder proposals at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 board nominees elected; Ernst & Young ratified as auditor with 99.3% votes for.","Say-on-pay approved with 91.27% of votes cast in favor.","Shareholder proposal to lower special-meeting threshold rejected (47.15% for).","Proposal for independent board chairman rejected (27.75% for).","Proposals on 10b5-1 plan restrictions (48.76% for), lobbying report (34.52% for), and antimicrobial resistance report (11.51% for) all rejected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375832,"accession_number":"0001104659-22-047560","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q1 sales $11.9B (+13.8%), adjusted EPS $1.73; full-year guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $11.9B, +13.8% reported, +17.5% organic; GAAP EPS $1.37, adjusted EPS $1.73.","Global COVID-19 testing sales $3.3B in Q1; full-year testing sales projected ~$4.5B, mostly in H1.","Full-year 2022 adjusted EPS guidance reaffirmed at least $4.70; GAAP EPS at least $3.35.","Nutrition sales -7% reported (-4.4% organic) due to infant formula recall; excluding recall, Nutrition +5%.","Medical Devices +7.4% reported (+11.5% organic); FreeStyle Libre sales ~$1.0B (+20.4% reported)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":11895000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394171,"accession_number":"0001104659-22-025612","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Abbott reduces board size from 13 to 12 effective April 29, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended by-laws to set board size at 12 directors, down from 13.","Change effective April 29, 2022; no reason cited.","Other by-law provisions remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394170,"accession_number":"0001104659-22-025072","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Abbott recalls Similac infant formula from Sturgis MI plant; reaffirms EPS guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proactive voluntary recall of Similac powder infant formulas from Sturgis, MI facility; primarily US and Canada.","FY2022 adjusted diluted EPS guidance reaffirmed at at least $4.70.","Q1 2022 will include one-time specified item for recall expenses (inventory destruction, etc.); amount not yet quantified.","Company states recall expenses are not expected to have a material impact on consolidated financial statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394169,"accession_number":"0001104659-22-007648","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2022-01-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q4 revenue $11.5B, adj EPS $1.32; FY2022 adj EPS guidance at least $4.70","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 GAAP diluted EPS $1.11; adjusted diluted EPS $1.32; sales $11.5B (+7.2% reported, +7.7% organic).","Full-year 2021 adjusted diluted EPS $5.21 (+42.7% YoY); total sales $43.1B (+24.5% reported).","COVID-19 testing sales $2.3B in Q4, $7.7B full year; company distributed over 1.4 billion tests since pandemic began.","FY2022 guidance: GAAP EPS at least $3.43, adjusted EPS at least $4.70; COVID testing sales forecast $2.5B.","Quarterly dividend of $0.47 per share declared, payable Feb. 15, 2022; marks 50 consecutive years of dividend increases."],"consensus_eps_estimate":null,"consensus_eps_actual":3.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":43075000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412771,"accession_number":"0001104659-21-149094","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2021-12-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abbott director Roxanne S. Austin will not stand for re-election in 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roxanne S. Austin informed Abbott Labs board on Dec 9, 2021 of her decision not to seek re-election.","Her current term ends at the April 2022 annual shareholders meeting.","She will step down at that time; no replacement or reason specified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412770,"accession_number":"0001104659-21-148608","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2021-12-10T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Abbott names CEO Robert B. Ford as Chairman; Miles D. White retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Miles D. White resigns as Executive Chairman and director, effective Dec 10, 2021.","CEO Robert B. Ford appointed Chairman of the Board, effective same date.","White retires after 38 years at Abbott; led transformation into health tech leader.","Board size reduced from 14 to 13; by-laws amended for remote shareholder meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412769,"accession_number":"0001104659-21-127874","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2021-10-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q3 sales $10.9B (+23.4%); adj. EPS $1.40 (+42.9%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.17; adjusted diluted EPS $1.40, up 42.9% vs 3Q20.","Global COVID-19 testing sales $1.9B; total organic sales growth 22.4%.","Full-year 2021 GAAP EPS guidance raised to $3.55-$3.65; adjusted $5.00-$5.10.","Board declared $0.45 quarterly dividend (payable Nov. 15, 2021); 49th consecutive annual increase.","Acquired Walk Vascular; received FDA approvals for Amplatzer Amulet, Portico TAVR, and Talisman PFO systems."],"consensus_eps_estimate":null,"consensus_eps_actual":2.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":31607000000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431435,"accession_number":"0001104659-21-111825","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2021-09-01T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Abbott appoints Patricia P. Gonzalez to Board of Directors; board size increased to 14","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patricia P. Gonzalez named to Abbott Laboratories Board of Directors effective August 30, 2021.","Board of Directors amended bylaws to increase board size from 13 to 14 members, effective same date.","No other director changes or compensatory arrangements disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-01T23:59:59+00:00|431435"}